Eisai Co (STU:EII) EBIT: €325 Mil (TTM As of Mar. 2026)


STU:EII Eisai Co Ltd STU:EII
74 GF Score
Price €21.11
GF Value €30.90
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Eisai Co EBIT?

Eisai Co STU:EII +0.24% 74 EBIT is €325 Mil as of Mar. 2026. GuruFocus rates STU:EII with a GF Score™ of 74/100 and a GF Value™ of €30.90 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Eisai Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €325 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eisai Co's annualized ROC % for the quarter that ended in Mar. 2026 was -1.51%. Eisai Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -6.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eisai Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.64%.


Eisai Co  (STU:EII) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eisai Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-224.872 * ( 1 - 59.78% )/( (5870.94 + 6106.541)/ 2 )
=-90.4435184/5988.7405
=-1.51 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8140.543 - 514.043 - ( 1755.56 - max(0, 2123.396 - 4605.761+1755.56))
=5870.94

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7899.303 - 450.067 - ( 1342.695 - max(0, 1854.769 - 4151.782+1342.695))
=6106.541

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Eisai Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-139.376/( ( (864.308 + max(1254.164, 0)) + (877.861 + max(1233.983, 0)) )/ 2 )
=-139.376/( ( 2118.472 + 2111.844 )/ 2 )
=-139.376/2115.158
=-6.59 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1364.165 + 1334.588 + 151.448) - (514.043 + 0 + 1081.994)
=1254.164

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1237.417 + 1403.922 + 167.748) - (450.067 + 0 + 1125.037)
=1233.983

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eisai Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=325.481/5767.700
=5.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co EBIT Related Terms


Eisai Co EBIT Historical Data

* Premium members only.

The historical data trend for Eisai Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co EBIT Chart

Eisai Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 429.97 330.36 394.30 400.79 307.08

Eisai Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.63 139.94 92.04 128.35 -34.84

STU:EII vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eisai Co's EV-to-EBIT falls into.


STU:EII
74GF Score
Eisai Co Ltd STU:EII
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eisai Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €325 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €325 Mil mean?
Eisai Co (STU:EII) has a EBIT of €325 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eisai Co.
Is Eisai Co's EBIT too high?
Eisai Co's current EBIT is €325 Mil. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's EBIT compare to ZTS?
Eisai Co's EBIT of €325 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eisai Co. Eisai Co's current EBIT is €325 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (STU:EII) is currently considered Significantly Undervalued. The stock's GF Value™ is €30.90, compared to a current price of €21.11 — trading 31.7% below its estimated fair value. The current EBIT is €325 Mil. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Eisai Co (STU:EII), the current EBIT is €325 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eisai Co (STU:EII) Overvalued in 2026?

Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued. The current stock price of €21.11 is trading 31.7% below its estimated GF Value™ of €30.90. GuruFocus considers Eisai Co to be Significantly Undervalued.

Key valuation signals for STU:EII:

  • EBIT: €325 Mil
  • GF Value™: €30.90 vs. price of €21.11 (31.7% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the STU:EII stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eisai Co Business Description

Address 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score

Get the complete analysis for STU:EII

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.11
Price
€30.90
GF Value